1. Home
  2. RDI vs AYTU Comparison

RDI vs AYTU Comparison

Compare RDI & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RDI

Reading International Inc

N/A

Current Price

$1.08

Market Cap

23.6M

ML Signal

N/A

Logo Aytu BioPharma Inc.

AYTU

Aytu BioPharma Inc.

HOLD

Current Price

$2.60

Market Cap

23.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDI
AYTU
Founded
1937
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Movies/Entertainment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.6M
23.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RDI
AYTU
Price
$1.08
$2.60
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$9.33
AVG Volume (30 Days)
38.2K
129.0K
Earning Date
11-14-2025
02-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$211,292,000.00
$63,696,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$13.42
$47.32
P/E Ratio
N/A
N/A
Revenue Growth
7.11
N/A
52 Week Low
$1.00
$0.95
52 Week High
$1.78
$3.07

Technical Indicators

Market Signals
Indicator
RDI
AYTU
Relative Strength Index (RSI) 42.10 49.33
Support Level $1.03 $2.45
Resistance Level $1.15 $2.77
Average True Range (ATR) 0.05 0.14
MACD 0.00 -0.03
Stochastic Oscillator 35.71 34.52

Price Performance

Historical Comparison
RDI
AYTU

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.

Share on Social Networks: